Apollo Hospitals Enterprise Limited (NSE: APOLLOHOSP, BSE: 508869) is a Chennai, Tamil Nadu-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹1,23,712 Cr, it ranks #89 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 46 in Hospitals and Healthcare Centers. At ₹8,526.00 (as of 16 Nov 2026), the share price is 6.0% below its 52-week high of ₹9,070.50 and 27.3% above its 52-week low of ₹6,696.50. The share price is up 11.6% over one year and down 0.9% over three months.
| Current Price | ₹8,526.00 |
|---|---|
| Market Cap | ₹1,23,712 Cr |
| NSE Symbol | APOLLOHOSP |
| BSE Code | 508869 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 63 |
| Return on Equity | 21.50% |
| Return on Assets | 8.47% |
| 52-Week Range | ₹6,696.50 – ₹9,070.50 |
| 1-Year Price Change | +11.6% |
| 3-Month Price Change | -0.9% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.24% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.apollohospitals.com |
| Revenue | ₹7,615 Cr |
|---|---|
| Net Profit | ₹660 Cr |
| Net Margin | 8.7% |
| EPS (Basic) | ₹43.74 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Apollo Hospitals Enterprise Limited reported revenue of ₹7,615 Cr in Q2 FY27, up 20.8% from ₹6,304 Cr in Q2 FY26 and up 8.1% from ₹7,044 Cr in Q1 FY27. It posted a net profit of ₹660 Cr for the quarter, against a net profit of ₹494 Cr in Q2 FY26 (up 33.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹5,592 Cr (Q4 FY25) to ₹7,615 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹7,615 Cr | ₹660 Cr | 8.7% |
| Q1 FY27 | ₹7,044 Cr | ₹610 Cr | 8.7% |
| Q4 FY26 | ₹6,606 Cr | ₹551 Cr | 8.3% |
| Q3 FY26 | ₹6,477 Cr | ₹516 Cr | 8.0% |
| Q2 FY26 | ₹6,304 Cr | ₹494 Cr | 7.8% |
| Q1 FY26 | ₹5,842 Cr | ₹441 Cr | 7.5% |
| Q4 FY25 | ₹5,592 Cr | ₹415 Cr | 7.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 28.02% of Apollo Hospitals Enterprise Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 55.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company’s healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent f
1. Healthcare Services-This segment operates hospitals and hospital based pharmacies. 2. Apollo Digital 24/7 Business-This segment operates pharmacy retail outlets. 3. Clinics-This segment operates clinics. 4. Others-This segment holds investments and fixed deposits.
1. Healthcare Services-50.5% 2. Retail Health & Diagnostics-7.4% 3. Digital Health & Pharmacy Distribution-42.8% 4. Others-0%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Dr. Agarwal's Health Care Limited | ₹17,568 Cr | 131.9 | 8.31% | ₹655 Cr | +9.3% |
Listed by market capitalisation. Ratios are shown for context only.
Apollo Hospitals Enterprise Limited is trading at ₹8,526.00, with a market capitalisation of ₹1,23,712 Cr.
Apollo Hospitals Enterprise Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Apollo Hospitals Enterprise Limited has a P/E of 63 and a return on equity of 21.50%.
Apollo Hospitals Enterprise Limited is listed on the NSE under the symbol APOLLOHOSP and on the BSE under the scrip code 508869.
Apollo Hospitals Enterprise Limited's share price is up 11.6% over one year and down 0.9% over three months. Its 52-week range is ₹6,696.50 to ₹9,070.50.
In Q2 FY27, Apollo Hospitals Enterprise Limited reported revenue of ₹7,615 Cr and net profit of ₹660 Cr, with basic EPS of ₹43.74 (consolidated, parsed from the company's exchange filing).
Apollo Hospitals Enterprise Limited reported revenue of ₹7,615 Cr in Q2 FY27, up 20.8% from ₹6,304 Cr in Q2 FY26 and up 8.1% from ₹7,044 Cr in Q1 FY27.
Promoters held 28.02% of Apollo Hospitals Enterprise Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.